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Background: Despite the progress made in the control of Neglected Tropical Diseases (NTD), schistosome and
soil-transmitted helminth infections are far from being effectively managed in many parts of the world.
Chemotherapy, the key element of all control strategies, is faced with some difficulties in terms of access to
treatment. Our study aims to describe the factors involved in the success or failure of the community-directed
intervention (CDI) approach through control programmes, which aims to achieve consistent high coverage at
affordable and sustainable costs in endemic areas.
Methods: The CDI approach was carried out from December 2007 to October 2008 in ten villages of the district of
Diéma, Mali. At inclusion, each child part of the study’s sample was interviewed and submitted for a physical
examination. The study focused on: data collection, treatment of the eligible population, evaluation of the
treatment coverage, performance of community drug distributors (CDDs), and the involvement and perception of
populations.
Results: A total of 8,022 eligible people were studied with a mean coverage rate of 76.7%. Using multiple
regression, it was determined that receiving praziquantel as treatment was associated with five factors: belonging
to the Fulani or Moorish ethnic minority versus the Bambara/Soninke, use of the central versus the house-to-house
drug distribution mode, the ratio of the population to the number of CDDs, the lack of supervision and belonging
to the age group of 15 years or above (p<0.05). As well as that, it was found that the presence of parallel
community-based programmes (HIV, tuberculosis) that provide financial incentives for community members
discouraged many CDDs (who in most cases are volunteers) to participate in the CDI approach due to a lack of
incentives.
Conclusions: The findings indicate that the success of the CDI approach depends on, amongst other things, the
personal characteristics of the respondents, as well as on community factors.
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Background
Schistosomiasis remains to be a major public health prob-
lem in many parts of Sub-Saharan Africa. It is estimated
that, globally, there are 207 million people infected with
one of the three major species of schistosomes [1], more
than 90% of which occur in Sub-Saharan Africa [1,2]. A
review of the relationship between infection and clinical
morbidity in Sub-Saharan Africa estimates that deaths
due to schistosomiasis may be as high as 200,000 per
year [3]. In Mali, schistosomiasis is mainly associated
with water resource development around dam con-
struction. The prevalence rate of the disease varies
from 40% in savannah villages to 80-90% in Office du
Niger and Bandiagara [4-6].
For the past 20 years, strategies have been developed
to control schistosomiasis in endemic areas. The key ele-
ments of these strategies were to control morbidity espe-
cially by selective treatment of heavy infections through
regular treatment of high-risk groups (schoolchildren,
fishermen and irrigation workers). It has been shown
that mass treatment and health education of the popula-
tion have significantly reduced transmission and morbid-
ity in countries and regions such as Brazil, Venezuela,
China, Indonesia, the Philippines, the Maghreb and the
Middle East [7]. Despite this progress, schistosomiasis is
far from being controlled in many parts of world. Be-
cause of the difficulties that exist in relation to access to
treatment, as well as the non-involvement of communi-
ties in the process of the distribution and treatment of
schistosomiasis, these strategies have failed to reach their
objectives. Today, less than 10% of the treatment-eligible
populations living in endemic regions of Africa, Asia
and the Americas receive annual treatment for schisto-
somiasis, intestinal helminth infections and/or tracho-
ma [2]. To improve access to treatment at affordable
and sustainable costs and, where possible, to improve
existing programmes, community-directed intervention
(CDI) has been presented as an alternative strategy to
control schistosomiasis and soil-transmitted helminths
(STHs). This approach has been adopted in several set-
tings [8-10] and has been successful in many countries
as part of the African Programme for Onchocerciasis
Control (APOC) [11,12], as well as for lymphatic filaria-
sis control [13,14]. In Mali, despite the Schistosomiasis
and Soil-transmitted Helminths National Control
Programme (PNSHs) adopting the CDI approach, the
programme has faced some difficulties which led to very
low coverage (<60%) in some districts (oral communica-
tion of the PNLSH’s coordinator).The overall objective of this study was to identify the
prominent factors affecting the programme’s failure to
improve access to treatment for all those at risk of both
overt and subtle morbidity due to schistosomiasis in the
health district of Diéma, Mali.
Methods
Experimental design and methods
Overall study design
The study focused on i) census and description of social
and demographical data at baseline, ii) choice and se-
lection of CDDs, iii) the social and cultural context of
the CDI approach, and iv) evaluation of the study out-
comes (treatment coverage, performance of CDDs, and
involvement and perception of populations) one month
after drug distribution started, and the issues related
to side effects 24 hours after drug administration.
The study was conducted between December 2007 and
November 2008.
Sampling design and sample size
The study’s design was an exploratory and descriptive
trial at the community level. The study unit, determined
by the implementation level of the health services, was a
village. The study population was comprised of an entire
village population. To measure the success of this de-
sign, four villages were selected based upon the preva-
lence of schistosomiasis, the functionality of the health
services and village accessibility. First, all functioning
health areas in the 13 villages were listed. Ten villages
were then selected from these health centres based on
the accessibility and the acceptance of the population to
participate in the study. The sample size of the eligible
population (children five to 15 years of age who would
provide urine and stool samples for analysis) was calcu-
lated according to the total population in each village,
the precision (5%), the attended prevalence in the study
site (60%) and the risk (alpha 5%) as described [15].
According to the statistical and demographical projec-
tion data, the population size in all ten villages was
9,806. However, to get more information on the popula-
tion and the number of tablets required, the research
team and the community drug distributors (CDDs) de-
termined the study population after a new census was
completed and the population of the villages was con-
firmed to be 8,022.
Study sites and health systems
In Mali, schistosomiasis is prevalent all over the country,
but is endemic only in four (35 districts) of the eight re-
gions. Following the Schistosomiasis Control Initiative
(SCI), the CDI strategy was successfully implemented in
the entire endemic district for schistosomiasis in Mali
since 2005. However, the CDI strategy failed in the
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coverage rate was lower than 60% [16]. Diéma was se-
lected as a study site because of the CDI strategy’s failure
to raise coverage, as expected, in this district compared
to the other districts.
The study took place in ten endemic villages in Diéma
(Figure 1). All the villages are accessible by car and
range in distance from seven to 20 kilometers from
Diéma.
Health services in Diéma are organised in two levels:
the community and the district level. Services at the
community level are delivered by a primary health care
centre (CHC). They are managed by selected community
representatives and led by a health officer appointed by
the government. The management of the district health
services (DHS) is done by the district management team
and headed by the District Medical Officer (DMO). The
CHC management team defers to the DMO as the over-
all leader of the district health system. The access to
health facilities varied from $0.4 to $1 per visit. In some
villages, the health charges were sometimes evaluated
into millet, rice, peanuts and/or poultry. Praziquantel
(PZQ) is not always available at the health centre – it is
only available during the mass drug distribution cam-
paigns. Normally, patients suffering from schistosomiasisFigure 1 Localization of the ten study villages (*) in the district of Diéwere examined (using questionnaires at the community
level, or using a microscope for stool and urine examin-
ation at the district reference health centre). After rou-
tine examination, each patient would pay for the PZQ
when he/she tested positive.
The social organisation of these communities was pri-
marily hierarchical, based on lineage. The leadership in-
cludes a village head and the village council comprising
of the heads of the village families. The village head and
the council are responsible for the general administra-
tion and decision making of the village. At the commu-
nity level, socio-economic activities are done according
to sex and age groups. In some villages, because of the
weight of tradition, women and men cannot mingle or
attend meetings together. The illiteracy rate is generally
high (70%) even if the policy of adult education in local
languages is well developed. The main ethnic groups are
Soninke and Bambara, and there are minority groups
such as Fulani and Moorish. Islam is the major religion.
The most common occupation is farming and cattle
rearing, with close proximity to standing water sources.
Young men in the region migrate extensively within, and
outside, the country for economic purposes.
There are two major seasons: a rainy season from
June/July to September/October, and a dry season whichma, Mali.
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and a hot season from February to May. Schistosomiasis
is seasonally transmitted from July to December.
Techniques of the study
Choice and selection of community-directed health workers
(CDHWs)
Community drug distributors (CDDs) were proposed
for, and selected by, the population. One CDD per 125
inhabitants was selected and trained. Prior to the train-
ing of the CDDs, each team conducted health education
using posters and/or verbal presentations in every CDI
study village to address the following issues: knowledge
of the disease, knowledge of treatment, attitude to treat-
ment, attitude to disease, attitude to the distributor, atti-
tude to good keeping and information/record sharing.
Following the training, the CDDs were expected to be
able to describe the major clinical manifestations of
schistosomiasis, the different methods of treatment
(house-to-house versus central point), and to have a
working knowledge of the methods of carrying out the
following PZQ distribution-related activities: community
mobilisation, household enumeration, guidelines on the
period and the duration of treatment, guidelines for the
exclusion criteria, correct dosage using height, recogni-
tion of minor reactions and when to refer adverse reac-
tions, basic record keeping, and to identify and report
the issues encountered during the distribution. These
guidelines could be modified when necessary. The dos-
age of PZQ for eligible members of the population was
determined using a person’s height measurement [17].
An easy-to-transport stick was calibrated to serve as the
measuring ruler. Tablets were swallowed in the presence
of the distributor.
Attitude and perception of community-directed health
workers (CDHWs) in the CDI strategy were scored on a
scale ranging from strongly agree to uncertain to
strongly disagree. Two major opinion items were consid-
ered to assess the health workers’ role in CDTI: i) the
CDHWs would like to participate in the training of com-
munity members to take responsibility for PZQ and
albendazole (ALB) distribution, and ii) the CDHWs
would like to take part in all decision-making processes
concerning the distribution of PZQ and ALB at the
community level.
The social and cultural context of community-directed
intervention (CDI)
The CDI strategy is an approach whereby community
members collectively: (i) discuss a health or develop-
mental challenge; (ii) design the approach to implement
the interventions in the community; (iii) identify the re-
sources to accomplish the task; and (iv) plan how, when,
where and by whom it will be implemented. Like in thecontrol of onchocerciasis [18], one aspect of the CDI strat-
egy for schistosomiasis control through PZQ distribution
is the appreciation and use of socio-cultural aspects of the
communities, such as the social structures, legal system,
resource mobilisation and sharing systems. Selection of
many CDDs and CDHWs is vital for achieving high-drug
coverage and integrating health programmes within the
CDI strategy, respectively. Having, at least, both female
and male CDHWs at the kinship level ensured prompt,
equitable and quality healthcare delivery for all categories
of community members. So, in some villages, females
were not eligible to be CDDs due to the social and cultural
context of that village.
In terms of why there was low morale amongst health
workers and CDDs, most claimed to have been busy at
the health units or at home, respectively, but many also
had low morale because of their poor remuneration. How-
ever, it was not clear if CDHWs and CDDs, when involved
in other health and development activities, could continue
distributing PZQ effectively and efficiently, whether in-
creased responsibilities would result in a higher drop-out
rate and whether they would demand monetary incentives
as a condition for services provided.
Community mobilisation
During the first visit to a village, the research team met
the village head or his representative to explain the pur-
pose of the study. The research team met the entire
community at a mutually convenient date. These meet-
ings provided an opportunity to review the problem and
transmission of schistosomiasis, and the benefits of con-
trolling the morbidity. The community engaged in a dis-
cussion regarding their experience with the disease,
snails, haematuria and systemic symptoms, such as ab-
dominal pain. The conditions for receiving PZQ and
ALB were outlined, procedures were reviewed for
recognising exclusion criteria (less than four years of age
and severely ill), and it was discussed that only eligible
persons would be treated, that the individual doses
would be determined by height and that possible side ef-
fects would be recognised.
Demographical assessment
A census of the whole population in each village was
performed at the onset of the study. The name of the
village; the date of the census; the household identifica-
tion number; the name of the head of the family; the
name of the first wife followed by her children in order
of decreasing age; and the sex, ethnicity, age and occu-
pation of the other family members were recorded.
Drug distribution
The CDDs identified those eligible for treatment at the
regular scheduled time of PZQ distribution. Children
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(observation or questioning) and seriously ill individuals
were deemed ineligible. The CDDs selected by villagers
went from house to house (house-to-house distribution
mode) or chose a central place in the village (central dis-
tribution mode) for the drug distribution. People who
could not be present were examined at the house of the
distributor and administered the drug there. The two
drugs, PZQ and ALB, are anthelminthic drugs used by
the National Control Programme, and are safe and toler-
able. The dose of PZQ was determined according to the
height of the patient [16] and it was suggested that pa-
tients eat before taking it. The dose of ALB was one tab-
let for all those eligible whatever the age.
Treatment coverage determination
The target population was the eligible population of
each village. All the treated and non-treated people were
recorded by the CDDs in a register. The treatment
coverage rate was calculated by dividing the number of
people who received PZQ and ALB by the total popula-
tion of the village. The geographical coverage was deter-
mined by ethnicity, geographical position of families in
the village and the individual’s occupation.
Evaluation of the performance of the CDDs
The performance of the CDDs was assessed by randomly
selecting interviewees from 10% of all households. All
members of the sampled households were interviewed
to determine if they received and were administered the
drugs. In the event that no household members required
therapy, explanations were recorded. The height of each
individual was re-measured in order to crosscheck with
the dose of the PZQ they received. People above 15
years of age were allowed to self-respond, however, for
younger children, a guardian responded. The head of the
household was also interviewed with respect to aware-
ness of the drug delivery programme and its purpose.
Evaluation of the community involvement and
acceptability
A questionnaire was administrated to the heads, as well
as to the councillors, leaders and healers, of each village.
The questionnaire determined the success of each village
in implementing the activities of the CDI: how they re-
ceived the research team, how they mobilised their pop-
ulations for the implementation of the CDI strategy,
how they selected their CDDs (number and quality), and
what resources they committed to support the activities
of the CDI.
Record keeping
Record keeping was standardised for all study villages.
Data were collected in registry, except for interviews forwhich a guide was used. Each distributor had a list of all
members of the villages. The following information was
asked in the questionnaire: region, village, house num-
ber, name, sex, age, relationship to the head of the
household, height, number of the eligible population,
number of people treated, severe adverse reactions,
number of tablets received, number of tablets distributed
and remarks.
The issues of adverse side effects
A side effect or incidence of a symptom is defined as a
symptom absent before the treatment and experienced
after the treatment. Amelioration of a symptom is de-
fined as a symptom that was experienced before the
treatment and was no longer present 24 hours after the
treatment. To describe the side effects associated with
PZQ administration, a questionnaire was administered
immediately, and 24 hours, after treatment whereby chil-
dren were asked whether they needed any medical as-
sistance or felt any of the following symptoms: dizziness,
headache, sleepiness, fatigue, vertigo, abdominal pain,
cramps, nausea, vomiting, diarrhoea, bloody stools,
lower back pain and urticaria/rash. Meanwhile, parents
or teachers were also invited to respond on behalf of
their children about whether they experienced any of the
stated symptoms prior to the treatment and at 24 hours
after the treatment. The CDDs were trained to recognise
and manage any adverse events related to PZQ and ALB
administration. In the case of serious adverse events, the
CDDs were invited to refer the patients to the CHC.
Data processing and analysis
Each of the village CDDs entered all data on the popula-
tion and the drugs administered. Quantitative data, in-
cluding variables of acceptability, awareness of drug
distribution and its purpose (by questionnaire adminis-
tered to a sample of a household or their representative),
the treatment coverage (characteristics of the respon-
dents such as age, gender and ethnicity; design; number
of distributors; method of CDDs’ selection; CDDs’ edu-
cation and occupation; sex of the distributor; mode of
distribution; and supervision) were entered into a com-
puter and analysed using EPINFO 6.0 for trends and fre-
quencies. A chi2 test was used for categorical variables,
and logistic regression was used to test associations be-
tween factors and the variables they influence. P values
less than 0.05 were considered to be significant.
Qualitative data from the process (sensitisation and
planning of mass drug distribution, training and selec-
tion of CDDs, development of communication for social
change (CFSC), drug procurement and distribution, and
record keeping) were collected using observations notes,
focus group discussions (FGDs) and in-depth interviews.
They were transcribed and entered into a computer with
Table 1 Treatment coverage per village (% in
parenthesis) in the Diéma district, October 2008
Treatment villages Total No. treated No. not treated
Fangoune Kagoro 754 588 (78.0) 190 (24.3)
Fangoune Massassi 722 591 (81.9) 131 (18.1)
Fangoune Bambana 602 386 (64.1) 216 (35.9)
Dampa 810 665 (82.1) 145 (17.9)
Bilibani 487 351 (72.1) 136 (27.9)
Debo Massassi 884 714 (80.8) 170 (19.2)
Debo Bambana 1221 837 (68.6) 384 (31.4)
Debo Kagoro 478 388 (81.2) 90 (18.8)
Guemou 1005 675 (67.2) 330 (32.8)
Kana 1059 961 (90.7) 98 (9.3)
Total 8022 6156 (76.7) 1866 (23.3)
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analysis of the process described above. The qualitative
study in the form of descriptions, opinions or discus-
sions was used to describe the beliefs and motivations
that underline the access to treatment for all those at
risk of schistosomiasis. The rationale of the qualitative
study was to identify factors associated with the coverage
rate (high and/or low rate) in order to improve the strat-
egy. It also helped to explain or clarify findings from the
analysis of the quantitative data. The qualitative study
was carried out one month after the start of the drug
distribution. It included a FGD and in-depth interviews.
A FGD lasting from one to two hours was led by a
trained moderator. The FGD was held in five randomly-
selected villages from the list of the study-site villages. In
each village, ten households were randomly selected: one
woman and one man (adults over 15 years) from each
household (i.e., 20 respondents per village) were se-
lected. Two groups for discussion (one for women and
the other for men) were constituted. Each group was
interviewed using a questionnaire aiming to capture re-
spondents’ opinions, beliefs and motives.
The in-depth interviews were structured to establish
attitudes, beliefs and knowledge, and were conducted in
the five selected villages. Three series of interviews were
held in each village: i) the village heads and leaders, ii)
the distributor(s) or the person responsible for the PZQ
distribution, and iii) the members (adults) of the ten
households in the villages.
All data were presented in the form of narratives, fre-
quency tables and histograms. Frequencies, means and
standard deviations were calculated and included socio-
demographic variables (gender, age, household size, etc.),
socio-economic statuses, as well as others.
Ethical considerations
The proposal was reviewed and approved by the Institu-
tional Review Board (IRB) of the Faculty of Medicine,
Pharmacy and Dentistry at the University of Bamako.
Community consent was obtained before starting the
study. A consent form (or assent form for minors) was
signed by each study participant.
Results
Treatment coverage of praziquantel and albendazole
A total of 8,022 people were studied in the survey,
according to the community drug distributor (CDD)
registry. At the end of treatment, the CDDs documented
all eligible villagers who received medication. Based on
the results recorded in Table 1, the mean coverage rate
was 76.7% (6156/8,022) (range: 64.0% to 90.7%). Nearly
80% (78.2%) of school-age children were reached. Over-
all, 60% of the study villages had a coverage rate above
75%, with treatment coverage significantly differingbetween villages (p<0.01). The mean age of people who
received praziquantel (PZQ) and albendazole (ALB)
(24.5 years) did not significantly differ from those who
did not require therapy (24.7 years). There were more
females (52.2%) than males (47.8%), especially in the age
group 15–34 years (p<0.01). However, the coverage did
not vary between the sex (76.4% versus 76.3% for fe-
males and males, respectively). The pattern of treatment
coverage did not vary significantly between sex among
the different age groups (p>0.05) either, except for the
35–44 year old age group (p<0.01).
Analysis of the treatment coverage (those who took
PZQ and ALB) by sex, age, ethnicity, mode of distribu-
tion and treatment ratio (population ration to CDDs) in
eligible villagers (Table 2) showed that 78.1% of people
under 15 years of age required medication compared
with 75.3% of those above 15 years of age (p<0.01).
There was a significant difference in compliance be-
tween ethnic groups: 77.3% of the 6,978 participants
reported as belonging to the Bambara/Sarakolle group
compared with 70.4% to the Fulani/Moorish group
(p<0.01). In one village where the mode of distribution
was centralised, 67.1% of the 1,005 eligible inhabitants
received medication, compared to 78.3% of the 7,017
from villages with a house-to-house mode of distribution
(p<0.01). The number of distributors per community
ranged from one to seven. The ratio of the village popu-
lation to CDDs was commonly associated with coverage
(OR=3.40; IC= 2.73-4.24). In some villages, other avail-
able community members helped during the distribution
stage. In nine villages, where 74.2% of 7,005 people re-
ceived drugs, more than 250 people were treated per
CDD. This is in contrast to two villages where only 150
people were treated per CDD; 90.7% of 1,059 received
the drugs. It was also found that the presence of health
workers for supervision at the time of distribution led to
high coverage rates (p<0.01; OR=2.21 IC: 1.92-2.55).
Table 2 Treatment coverage by sex, age, ethnicity, mode of distribution and treatment ratio (population to CDDs
ratio) in eligible villages in the Diéma district, October 2008
Factor No Percent treated p OR 95% CI
Sex
Male 2984 76.4
Female 4168 76.3 0,97 1.00 0.90-1.11
Age group
< 15 years 3026 78.1
15 and above 4996 75.4 <0.01 1.17 1.05-1.30
Ethnicity
Bambara/Sarakolle 6978 77.3
Fulani/Moorish 1044 70.4 <0.01 1.43 1.24-1.65
Mode of distribution
Central 1005 67.2
House-to-house 7017 77.7 <0.01 1.16 1.05-1.27
Ratio of population to CDDs
150/CDD 1059 90.7
>=150/CDD 6963 74.2 <0.01 3.40 2.73-4.24
Presence of health workers
Health worker 1950 85.4
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that a person’s ethnic group and age group, the mode
of distribution, the population to CDD ratio and the
presence of a health worker to supervise were all
significantly associated with coverage rate increase
(Table 3). Ethnic group and age group are personal
characteristics of the respondents, while the mode of
distribution, the population to CDD ratio and the pres-
ence of health workers at the time of distribution are
community factors.
Overall, 23.3% (1,866/8,022) of the respondents did
not receive medication at the time of treatment. From
this group, 9% were excluded because they were under-
age. Another 11% were eligible, but were either sick,
pregnant or unaware of the distribution (205/1,866).Table 3 Factors associated with having received
praziquantel and albendazole in the Diéma district,
October 2008
Variables OR p IC 95%
Sex 0.97 0.67 0.87-1.08
Ethnic group 1.34 <0.01 1.16-1.55
Age group 1.13 0.03 1.01-1.26
Mode of distribution 1.45 <0.01 1.25-1.68
Population to DCM ratio 2.27 <0.01 1.74-2.97
Presence of a health worker 1.38 <0.01 1.16-1.66Only 1.7% refused to be treated. The pattern of absen-
teeism by age group showed that the problem was more
common in those aged 15–24 years (Figure 2). Ethnic dif-
ferences, however, did exist: only 2% of 297 Fulani and
Moorish and 10% of 1,569 Bambara and Sarakolle
complained that they had not been informed. Being absent
at the time of distribution was more common among




























Figure 2 Proportion of eligible people (by age group) who did
not take praziquantel as they were absent, Diéma, October 2008.
Dabo et al. Infectious Diseases of poverty 2013, 2:11 Page 8 of 11
http://www.idpjournal.com/content/2/1/11Treatment and side effects
Side-effect data were available for 1,884 children and
1,640 mothers and teachers. During administration of
the PZQ and ALB, side effects directly related to tablet
administration (e.g., choking or coughing) were very rare
(prevalence <0.1%) and not life threatening. In the ten
villages, all side effects were investigated 24 hours after
treatment. Most of the side effects were reported at
varying prevalence levels, from 4.6% of children
complaining about abdominal pain to 11.7% reporting
fatigue. Headaches (5.1%), vomiting (9.7%) and diarrhoea
(10.2%) were also found at significant levels. By contrast,
mothers reported very few children (<1.0%) displaying
any symptoms during the 24-hour follow-up.
Discussion
In the Diéma health district, the influence of social be-
haviour and cultural beliefs on public health interven-
tions was greater than expected, especially among
women. This is evident in the majority of the CDDs be-
ing men because women and, in particular younger
ones, were not accepted for this position. In some
villages, the two sexes could not mingle at a single
meeting place.
One of the main findings was that many CDDs
dropped out early due to a lack of incentive that was be-
ing provided (it was felt that the work load was too
heavy for no financial compensation). Regarding the
community interaction with the health services, the ma-
jority of the health workers did not visit villages regu-
larly. Only 40% of the population reported that the
District Director of Services (DDS) visited their commu-
nities. For 60% of the population, health workers visited
the villages only during a specific campaign, such as
immunisation and/or a cholera outbreak. Of those
interviewed, 70% reported that the services provided in
the communities are relevant to their needs and that
they were satisfied with them. In terms of the commu-
nity having an understanding of schistosomiasis and in-
testinal helminths, and their experiences with the
treatment, it was found that 98% knew about the disease
and 46% felt that it is a problem mainly because children
who have the disease are constantly ill. The disease
aetiology was attributed partly to a child’s normal bio-
logical development (45%), food (30%) and contact with
urine of those infected (20%). Over half (60%) of the
population felt that schistosomiasis could be cured. Of
those who believed it could be cured, ~50% thought
that it could be treated with traditional medicine and
the other half believed it could be done via modern
medicine. With regards to prevention, 6% thought that
the diseases caused by soil-transmitted helminths could
be prevented, but no prevention was proposed for
schistosomiasis.Despite the health education about the transmission
and prevention of the disease, standing water sources
continued to be used by populations for fishing or for
other domestic activities. After the rainy season, snails
concentrate in small standing water sources with high
levels of cercariae emerging. According to historical
data, Diéma is known to be an endemic area for schisto-
somiasis haematobium [19] and our findings from the
survey showed a high prevalence of S. haematobium
(78.4%) (data not presented here). In Niger, re-infection
begun five months after treatment and the initial preva-
lence of infection decreased from 74.5% to 47.1% [20].
The mean coverage rate, especially in school children,
achieved under community-directed intervention (CDI)
was higher than that recommended by the World Health
Organization [5]. Since 2002, the World Health Assem-
bly, WHA 54.19, requires that by 2010, any round of
anthelminthic treatment must be offered to at least 75%
of children aged six to 15 years. Experience in
community-directed treatment (ComDT) of onchocer-
ciasis [21,22] demonstrated that this treatment approach
was not merely effective in the short term, but also
proved to be sustainable in the long term. The success
of the experience achieved in onchocerciasis led to ex-
tensions of ComDT to treatment of other disease con-
trol programmes, such as lymphatic filariasis [23] and
schistosomiasis [8].
Though it is not yet known precisely what level of
treatment coverage is required to achieve elimination of
the disease, the coverage rate of 75%, especially in
school-age children, may be sufficient to interrupt trans-
mission. Experience of parasite control programmes has
shown that 75% coverage is an attainable target, deliver-
ing significant reductions in morbidity and preventing ir-
reversible sequelae. The results of the census showed
that coverage was higher in females than in males.
This may be a result of the intense migration among
males between the ages of 15–34 years travelling
within neighbouring countries (Senegal, Cote d’Ivoire) or
Europe and America. The income from these migrant
males contributed to more than 80% of family budgets.
With respect to the treatment prevalence, males and fe-
males were equal (76%). Conversely, 15–29 year-old fe-
males in Cameroon were considered to be too busy with
housekeeping activities and therefore less able to come
to ivermectin distribution points [24]. However, in our
study, the reasons for why eligible people did not receive
PZQ were the same for males and females. The low
coverage rate amongst 15-24-year olds (Figure 2) is often
observed in this age group and tends to be related to
economical concerns of this mobile population.
Absenteeism at the time of distribution was more
common among Fulani and Moorish populations
(70.3%) who were primarily migrant cattle breeders
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that some people (Fulani, Moorish and some resident
Bambara/Sarakolle) were absent from villages at the time
of distribution may be of epidemiological importance.
These people, as well as migrants, remain to be im-
portant parasite reservoirs and may re-infect snails by
shedding schistosome eggs upon return to the village.
The Fulani and Moorish present a very different case.
They live in separate settlements near the villages and
they do not integrate within the Bambara and
Sarakolle farm hamlets. They herd cattle in order to
find pasture land, which explains why absenteeism at
the time of distribution was a common reason for not
receiving PZQ and ALB.
To meet CDI objectives, CDDs and health workers
may need to pay more attention to ethnic diversity in
order to build specific treatment schedules according to
ethnic presence in the village. Even if the house-to-house
mode distribution appeared to be efficient in this study,
the success of this approach to increase coverage de-
pends on the number of CDDs and their involvement in
all aspects of distribution. Qualitative data helped to ex-
plain some findings. The following FGD comments re-
veal how villagers perceived drug distribution. Some said
‘that the drug would affect them’. ‘It makes [me] giddy. I
didn’t use [it] because of side effects’. Some individuals
who were unable to be present for the drug distribution
reported that they refused to take the drugs after hearing
about their side effects. ‘It causes stomach aches,
vomiting and dizziness for those who use it. Some of
them cannot work.’ Overall, side effects occurred in
12.3% of the eligible participants (dizziness – 5.9%, nau-
sea, vomiting – 5.5% and others – 0.9%). Some individ-
uals initially rejected therapy but later took it ‘because
they got information from others that the drug was
good’. ‘It works.’
In-depth interviews with the Fulani or Moorish iden-
tified some of the reasons why their coverage rate was
lower. ‘We are migrants and most of us are following
flocks and herds outside the village.’ The native vil-
lagers, the Bambara and Sarakolle, confirmed the prob-
lem during the FDGs. ‘At the time of the distribution,
even if the Fulani and Moorish were present at hamlets
(two to four kilometres from village), they did not move
to the village for treatment but preferred to be treated
in their own gomes’.
The role of community participation in improving
coverage was identified by the CDDs during the FGDs.
The comments by the CDDs distinctly differed to the
present coverage status. The comments from those vil-
lages with low coverage were more negative: the com-
munity members were not involved in any other form of
treatment besides the drug they took, they did nothing
to assist during the distribution and the community didnot cooperate as expected. ‘I did not get any kind of as-
sistance from anybody in carrying out the distribution.’
In high coverage villages, the following positive com-
ments from the CDDs were common: ‘the community
members assisted in the area of health education, mobil-
isation and procurement of census materials; the com-
munity showed an interest in the programme as they
helped me on the farm; community members brought a
notebook for the census and a drug box; they fetched
water when we were using the drug; they helped me to
hold stick when I was distributing the drug’.
Besides these comments by the CDDs, village leaders,
during the FGDs, typically gave the following comments,
especially in low-coverage villages: ‘In our village, most
of the CDDs refused drug distribution because they pre-
fer to be compensated for their participation, such as be-
ing noted in other programmes (i.e., HIV). Out of every
five to six CDDs at baseline, only one or two of them
finally accepted to do the job’. Sometimes, various pro-
grammatic communication problems were identified
by the leaders and community members: ‘On the dis-
tribution day, many residents were not around. Some
men, and especially eligible children, took out their
cattle for grazing’.
In high coverage villages, the role of the CDDs was
judged to be positive: the CDDs showed an interest in
the programme because their goal was to distribute
drugs to all the villagers. When some community mem-
bers were absent on the date of distribution, the CDDs
returned twice or three times to the same family to
meet them or waited for a period of time before
returning to administer the drug. Even if people showed
side effects, the CDDs encouraged them to use the
drug, reassuring the villagers that the problems will
eventually disappear. In fact, going from house to house
was the best thing because they were able to reach even
those who cannot walk. This was effective as people felt
this was not interfering with their daily duties and be-
cause the CCDs were people they knew, they thus had
faith in them.
Conclusion
The aim of the CDI approach was to provide better
coverage rates, or at least to get them to be as good as
the traditional programme-designed strategies (and also
to ensure sustainability of long-term programmes). The
findings of this study demonstrated that participatory
methods could be incorporated in an effective control
strategy for distribution of PZQ and ALB for treatment
of schistosomiasis and intestinal helminthiasis. The most
important factor for successful implementation of the
CDI approach was primarily community mobilisation in
order to get a high number of distributors devoted
to the process. In all villages, community distributors
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tion. More attention to the personal characteristics of
the respondents and to community factors may also help
raise the coverage rates.
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